ICH S1 prospective evaluation study and weight of evidence assessments: commentary from industry representatives.

Industry representatives on the ICH S1B(R1) Expert Working Group (EWG) worked closely with colleagues from the Drug Regulatory Authorities to develop an addendum to the ICH S1B guideline on carcinogenicity studies that allows for a weight-of-evidence (WoE) carcinogenicity assessment in some cases, rather than conducting a 2-year rat carcinogenicity study. A subgroup of the EWG composed of regulators have published in this issue a detailed analysis of the Prospective Evaluation Study (PES) conducted under the auspices of the ICH S1B(R1) EWG. Based on the experience gained through the Prospective Evaluation Study (PES) process, industry members of the EWG have prepared the following commentary to aid sponsors in assessing the standard WoE factors, considering how novel investigative approaches may be used to support a WoE assessment, and preparing appropriate documentation of the WoE assessment for presentation to regulatory authorities. The commentary also reviews some of the implementation challenges sponsors must consider in developing a carcinogenicity assessment strategy. Finally, case examples drawn from previously marketed products are provided as a supplement to this commentary to provide additional examples of how WoE criteria may be applied. The information and opinions expressed in this commentary are aimed at increasing the quality of WoE assessments to ensure the successful implementation of this approach.
Competing Interests: Author JD was employed by the company Alnylam Pharmaceuticals. Author MG was employed by the company Organon. Author SH was employed by the company Formerly ASKA Pharmaceutical Co., Ltd. Authors JL and FS were employed by the company Merck & Co., Inc. Author TN was employed by the company Boehringer Ingelheim Pharma GmbH & Co. KG. Author RS was employed by the company Takeda Development Center Americas, Inc. Author KT was employed by the company Astellas Pharma Inc. Author JV was employed by Lilly Research Laboratories.
(Copyright © 2024 Vahle, Dybowski, Graziano, Hisada, Lebron, Nolte, Steigerwalt, Tsubota and Sistare.)